Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
TEVAPHARMIND SP ADR
(NY:
TEVA
)
51.47
USD
+0.24 (+0.47%)
Official Closing Price
/ Updated:
8:04 PM EDT, Sep 23, 2016
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
3,127,561
Open
51.01
Bid (Size)
51.40 (100)
Ask (Size)
51.55 (100)
Prev. Close
51.23
Today's Range
50.85 - 51.51
52wk Range
48.01 - 66.55
Shares Outstanding
914,000,000
Dividend Yield
2.64%
Performance
YTD
-21.18%
-21.18%
1 Month
+0.53%
+0.53%
3 Month
+6.06%
+6.06%
6 Month
-4.44%
-4.44%
1 Year
-13.26%
-13.26%
Top News
More News
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
September 22, 2016
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III registration trial studying the...
Read More
from
Business Wire News Releases
Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
September 20, 2016
Novel Nerve Growth Factor (NGF) Antibody Has Potential to Address Limitations of Current Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Opioid Therapies
Read More
from
PR Newswire
More News
Read More
Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
September 20, 2016
from
Business Wire News Releases
Negative impact largely priced into shares of EpiPen-maker Mylan, analyst says
September 22, 2016
category
Teva Pharmaceutical Industries Ltd
,
Investing/Stock Market
,
Health Care
, and 4 more.
from
CNBC.com News
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
September 22, 2016
category
Media
,
Analyst Color
,
M&A
, and 13 more.
from
Benzinga
BRIEF-Teva announces data from second phase 3 study of SD-809
September 22, 2016
category
companyNews
from
Reuters: Company News
3 Dirt-Cheap Dividend Stocks You Can Buy Right Now
September 24, 2016
category
ABBV
,
GILD
,
AGN
, and 1 more.
from
Motley Fool
Allergan CEO says 'the American people deserve to be angry' at price gouging
September 21, 2016
category
Tobira Therapeutics Inc
,
Investing/Stock Market
,
Investing/Stock Market/Stock Picks
, and 7 more.
from
CNBC.com News
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
September 21, 2016
category
VTAE
,
TEVA
,
GILD
, and 16 more.
from
Benzinga
New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting Reversible Contraceptives List
September 20, 2016
category
News
,
FDA
,
Benzinga
, and 14 more.
from
Benzinga
UPDATE 1-West Virginia investigating Mylan over EpiPen pricing
September 20, 2016
category
companyNews
from
Reuters: Company News
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates
Bots go here